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Abstract
Aims Dabigatran is largely cleared by renal excretion.
Renal function is thus a major determinant of trough da-
bigatran concentrations, which correlate with the risk of
thromboembolic and haemorrhagic outcomes. Current da-
bigatran dosing guidelines use the Cockcroft–Gault (CG)
equation to gauge renal function, instead of contemporary
equations including the Chronic Kidney Disease Epide-
miology Collaboration (CKD-EPI) equations employing
creatinine (CKD-EPI_Cr), cystatin C (CKD-EPI_Cys) and
both renal biomarkers (CKD-EPI_CrCys).
Methods A linear regression model including the dabig-
atran etexilate maintenance dose rate, relevant interacting
drugs and genetic polymorphisms (including CES1), was
used to analyse the relationship between the values from
each renal function equation and trough steady-state
plasma dabigatran concentrations.
Results The median dose-corrected trough steady-state
plasma dabigatran concentration in 52 patients
(38–94 years) taking dabigatran etexilate was 60 lg/L
(range 9–279). The dose-corrected trough concentration in
a patient on phenytoin and phenobarbitone was [3 stan-
dard deviations below the cohort mean. The CG, CKD-
EPI_Cr, CKD-EPI_Cys and CKD-EPI_CrCys equations
explained (R2, 95 % CI) 32 % (9–55), 37 % (12–60), 41 %
(16–64) and 47 % (20–69) of the variability in dabigatran
concentrations between patients, respectively. One-way
analysis of variance (ANOVA) comparing the R2 values for
each equation was not statistically significant (p = 0.74).
Discussion Estimates of renal function using the four
equations accounted for 32–47 % of the variability in da-
bigatran concentrations between patients. We are the first
to provide evidence that co-administration of phenytoin/
phenobarbitone with dabigatran etexilate is associated with
significantly reduced dabigatran exposure.
Key Points
Estimated GFR using the Cockcroft–Gault equation,
and modern creatinine- and cystatin C-based
equations, was found to explain 32–47 % of the
variability in trough steady-state dabigatran plasma
concentrations between patients.
We are the first to show that co-administration of
dabigatran etexilate with phenytoin and/or
phenobarbitone is associated with markedly reduced
dabigatran exposure.
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1 Introduction
Dabigatran, a thrombin inhibitor, is an oral anticoagulant
that is used especially for thromboprophylaxis in the set-
ting of atrial fibrillation (AF) [1–3]. It is administered
orally as the prodrug dabigatran etexilate. Higher plasma
dabigatran concentrations have been shown to be associ-
ated with a decreased risk of thromboembolism and an
increased risk of haemorrhage [4]. There are several factors
that may determine differences in dabigatran concentra-
tions between individuals (Table 1) [5–14]. For example,
the oral availability of dabigatran etexilate is affected by
stomach pH, and consequently, drugs that increase gastric
pH (e.g., proton-pump inhibitors) have been found to
reduce the dabigatran concentrations [11, 12]. Dabigatran
etexilate is also a substrate for the efflux transporter
P-glycoprotein (P-gp) in the intestinal wall [10]. Drugs that
alter P-gp function (e.g., amiodarone), and genetic poly-
morphisms in the ABCB1 gene, which encodes P-gp, are
associated with altered oral availability [5, 13]. Following
entry into the circulation, hepatic carboxylesterase-1
(CES1) is responsible for the metabolism of dabigatran
etexilate to dabigatran, via two parallel intermediate
metabolites, BIBR 951 and BIBR 1087 [13]. Genetic
polymorphisms in the CES1 gene have been found to alter
dabigatran concentrations [13].
As dabigatran is mainly cleared by the kidneys (fraction
excreted unchanged in urine of 0.8), renal function is a
major determinant of dabigatran concentrations [15, 16].
Glucuronidation is responsible for the remaining 20 % of
dabigatran clearance [15, 17]. The dabigatran glucuronides
are equipotent to dabigatran against thrombin, and appear
to be primarily renally cleared [15, 17]. Hence, it has been
recommended that maintenance dose rates of dabigatran
etexilate should be adjusted to take renal function into
account [5, 18].
The standard representation of renal function is the
glomerular filtration rate (GFR) [19, 20]. The gold standard
methods for determining GFR are based on the clearance of
renally eliminated exogenous compounds [21]. However,
as these are inconvenient for routine clinical use, several
equations for estimating GFR based on the measurement of
endogenous compounds are currently recommended [19,
20]. The Cockcroft–Gault (CG) equation [22], which uses
the endogenous renal biomarker, creatinine, has been used
for many years to gauge renal function in relation to drug
dosing [23]. More recently, the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) 2009 equation
[24] was developed using creatinine assays standardised
against the isotope dilution mass spectrometry (IDMS)
method, and has become one of the most commonly used
GFR equations [25, 26].
Cystatin C is an alternative renal function biomarker
that has received considerable attention [27]. Whereas
creatinine assay standardisation was introduced in 2006,
the first certified reference material (ERM-DA471/IFCC)
for standardising cystatin C assays has only been available
since 2010 [28]. Hence, while a multitude of cystatin
C-based GFR equations have been developed over the
years [29], only a few have employed assays that are
traceable to ERM-DA471/IFCC [30, 31]. These include the
CKD-EPI equations that feature cystatin C [30].
All GFR equations are expected to explain some of the
variance in dabigatran concentrations. However, to our
knowledge, the abilities of the existing renal function
equations to describe differences in dabigatran concentra-
tions have not been assessed and compared [32]. The
potential finding that one of the CKD-EPI equations is
Table 1 Covariates of dabigatran plasma concentrations
Covariate Mean exposure ratio
(90 % CI)a
Proton-pump inhibitor [12] 0.80 (0.67–0.95)
Intestinal P-gp function
Ketoconazole [5] 2.50 (NA)
Dronedarone [6] 1.99 (1.79–2.21)
Verapamil [8] 1.71 (1.34–2.15)
Amiodarone [5] 1.60 (NA)
Quinidine [5] 1.50 (NA)
Clarithromycin [9] 1.49 (NA)
Ticagrelor [59] 1.46 (NA)
Clopidogrel, loading doseb [7] 1.35 (1.07–1.69)
rs4148738 [13] 1.12 (1.08–1.17)
rs1045642 [14] 1.08 (NA)





rs2244613 [13] 0.85 (0.81–0.90)
rs4122238 [13] 0.86 (0.81–0.91)





AUC0–? area under the concentration-time curve from zero to
infinity, CES1 carboxylesterase-1, NA not available, P-gp
P-glycoprotein
a This represents the mean ratio of the AUC0–? of individuals with
the covariate to healthy controls without the covariate, or, for genetic
polymorphisms, the mean ratio (95 % CI) of either peak (P-gp) or
trough (CES1) concentrations of single allele carriers to wildtype
b Steady-state dosing of clopidogrel has not been shown to signifi-
cantly alter dabigatran AUC0–? [7]
c May be associated with decreased dabigatran AUC0–? [10]
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superior to the CG equation could lead to changes to the
current guidelines, which currently stipulate that the CG
equation is used to guide dabigatran etexilate dosing [5].
Further, the impact of the different GFR equations on the
dose selection of dabigatran etexilate has not been exam-
ined. The aims of the current study were to evaluate the
correlation of trough concentrations of dabigatran at
steady-state with four contemporary renal function equa-
tions, and to simulate the differences in dosing resulting
from the use of these equations (Table 2).
2 Methods
2.1 Study Design
This observational study was carried out in Christchurch,
New Zealand, between July 2012 and May 2013. The
Upper South B Regional Ethics Committee, New Zealand
provided ethical approval for this study (URB/12/02/009
and URB/12/02/009 AM01). Each participant in the study
provided written consent.
2.2 Participants
Patients treated with dabigatran etexilate for non-valvular AF
and aged C18 years were included if they had been on the
same dose rate for at least 7 days and had not missed any doses
in the 7 days prior to the study day (self-reported). Patients
were assumed to have steady-state dabigatran concentrations
after dosing for 7 days as the half-life of dabigatran has been
reported to range from 14–28 hours for patients with a GFR
of 21–110 mL/min [16]. Patients were excluded if, on the
study day, they required hospitalisation for an acute illness.
Patients were otherwise eligible if they were outpatients in the
community, electively admitted for diagnostic tests or were
inpatients for physical rehabilitation. Age, sex, weight,
height, dabigatran etexilate dose rates, co-prescribed medi-
cations and comorbidities were recorded. Using these data,
we calculated each individual’s CHA2DS2-VASc (1 point for
each of Congestive heart failure, Hypertension, Diabetes
mellitus, Vascular disease, Age 65–74 years, Female sex, 2
points for each of Age C75 years, Previous stroke) and HAS-
BLED (1 point for each of Hypertension, Abnormal renal/
liver function, Stroke, Bleeding history or predisposition,
Labile international normalized ratio, Elderly, Drugs/alcohol
concomitantly) scores, which estimate thromboembolic and
haemorrhagic risks, respectively [33, 34].
GFR was estimated for each individual using the four
equations listed in Table 2. The results from the various
CKD-EPI equations were converted from units of mL/min
per 1.73 m2 to mL/min according to Eq. 1:




where the body surface area of the individual (BSA) was
calculated using Mosteller’s equation [35–39].
2.3 Sample Collection and Laboratory Analysis
Each patient provided a set of venous blood samples
10–16 hours post-dose for measuring plasma creatinine
and cystatin C concentrations, plasma free thyroxine and
thyroid-stimulating hormone (TSH) concentrations (BD
Vacutainer lithium heparin tubes); Hemoclot Thrombin
Inhibitor times (HTI, Hyphen BioMed, Neuville-sur-Oise,
France) (BD Vacutainer citrate tubes); plasma dabigatran
concentrations (BD Vacutainer K2 ethylene diamine tet-
raacetic acid [EDTA] tubes). Blood cells from the EDTA
tubes were used for genotyping. Serum creatinine and
cystatin C concentrations were only measured at a single
point in time for each participant, as intra-individual vari-
ance (coefficient of variation, CV) of these biomarker
Table 2 GFR equations
Equation (units) Description
CG (mL/min) GFR ¼ 140ageð ÞTBW
0:815½serum creatinine  0:85ðfemaleÞ
CKD-EPI_Cr a (mL/min per 1.73 m2)







CKD-EPI_Cys (mL/min per 1.73 m2)
GFR ¼ 133  min ½serum cystatin C
0:8 ; 1
 0:499
max serum cystatin C½ 
0:8 ; 1
 1:328
0:996age  0:932 ðfemaleÞ
CKD-EPI_CrCysb (mL/min per 1.73 m2)
GFR ¼ 135  min ½serum creatinine
88:4j ; 1
 a
max serum creatinine½ 
88:4j ; 1
 0:601
min ½serum cystatin C
0:8 ; 1
 0:375
max serum cystatin C½ 
0:8 ; 1
 0:711
0:995age  0:969 ðfemaleÞ
CG Cockcroft–Gault equation, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration equation, Cr creatinine, Cys cystatin C, GFR
glomerular filtration rate, TBW total body weight
a a is 0.7 for females and 0.9 for males, b is -0.329 for females and -0.411 for males
b Where k is 0.7 for females and 0.9 for males, a is -0.248 for females and -0.207 for males
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concentrations has been reported to be around 7 % in
clinically stable individuals [40].
Serum creatinine was measured using an Abbott Ae-
roset analyser (Abbott Park, IL, USA) by the modified Jaffe
reaction. This was IDMS-aligned for the period of this
study and had an inter-day CV of \4.0 %. Serum cystatin
C was measured using a particle-enhanced nephelometric
immunoassay on a Behring Nephelometer II analyser
(Siemens Diagnostics, Marburg, Germany), with a CV
\4.5 % [41]. The use of a contemporary Siemens assay for
cystatin C is consistent with the recommendations by
Shlipak et al. [42]. Siemens calibrators standardised to the
international certified cystatin C reference material (ERM-
DA471/IFCC) were employed [28]. Serum free thyroxine
(CV\5.8 %) and TSH (CV\6.4 %) were measured using
an Abbott Architect analyser (Abbott Park, IL, USA) by a
chemiluminescent microparticle immunoassay (CMIA).
The HTI assay was performed on an ACL TOP 700
instrument (Instrumentation Laboratory, Bedford, MA,
USA) and had an inter-day CV of \11 %.
2.3.1 Plasma Dabigatran Assay
Plasma dabigatran concentrations were measured using a
validated liquid chromatography–mass spectrometry (LC–
MS/MS) method, based on a previously published method
[43]. Briefly, 50 lL plasma was added to 450 lL of
internal standard. Internal standard consisted of 10 lg/L of
[13C6]-dabigatran in methanol and 0.1 mmol/L aqueous
HCl (9:1, v/v). This was vortexed and then centrifuged at
15,000 g for 5 minutes for protein precipitation. A 50 lL
aliquot of clear supernatant was added to 500 lL of water,
and transferred to an autosampler vial. A 10 lL volume
was injected into the LC–MS system (Agilent 1290 Infinity
Series High Performance Liquid Chromatograph connected
to an Agilent 6460 Series Triple Quadrupole Mass Spec-
trometer, Agilent Technologies, Santa Clara, CA, USA).
For the range of 5–1,000 lg/L, the intra- and inter-day
precision (CV) values were B11.8 % and bias was B8.3 %.
2.3.2 ABCB1 and CES1 Genotyping
DNA was collected from white blood cells using guanidine
isothiocyanate extraction [44]. Genotyping for ABCB1
single nucleotide polymorphisms (SNPs) rs1045642,
rs1128503 and rs4148738 was performed using the pre-
designed SNP TaqMan assays C_7586657_20,
C_7586662_10 and C_1253813_10, respectively. ABCB1
rs2032582 is a tri-allelic SNP, and therefore separate pre-
designed assays, C_11711720D_40 and C_11711720C_30,
were needed in order to identify the two minor alleles
ABCB1 2677A and ABCB1 2677T. Results of each ABCB1
rs2032582 assay were analysed separately and then
combined to determine the overall minor allele frequency
for this SNP. Genotyping for CES1 SNPs rs8192935,
rs2244613 and rs412223 was performed using custom-
designed SNP TaqMan assays. All genotyping assays
were sourced from Applied Biosystems (Applied Biosys-
tems, Carlsbad, CA, USA). Each reaction was performed in
a total volume of 5 lL following the recommendations of
the manufacturer and run on a Roche LightCycler 480
Real-Time PCR System (Roche Diagnostics Corporation,
IN, USA) in 384-well format. Briefly, the thermal cycling
conditions comprised an activation step of 10 minutes at
95 C, followed by 40 cycles of denaturation (15 s at
92 C) and annealing/extension (1 min at 63 C). Geno-
types were assigned using endpoint genotyping analysis
software (Roche Diagnostics Corporation, IN, USA). The
accuracy of the TaqMan assays was confirmed by repeat
analysis of 10 % of samples. Concordance between origi-
nal and repeat genotype calls was 100 % for the two
assays. PLINK software was used to test for deviations in
Hardy–Weinberg Equilibrium (HWE) [45].
2.4 Statistical Analysis
Statistical analysis was performed using GraphPad Prism
(version 6.03, GraphPad Software, La Jolla, CA, USA) and
SPSS (IBM SPSS Statistics for Windows, version 20.0.0.2,
IBM Corporation, Armonk, NY, USA). A p-value of\0.05
was considered statistically significant.
2.4.1 Correlation Between Glomerular Filtration Rate
(GFR) Equations and Dabigatran Concentrations
The primary aim of the correlation analysis was to assess
the correlations of the estimated GFR values with dabiga-
tran concentrations normalised for all other known covar-
iates. This analysis was conducted in two stages, as
follows.
1. Dose-corrected trough plasma dabigatran concentra-
tions (dabigatrantrough, with units of lg/L per mg/day)
were regressed against non-renal clinical factors
(covariates) known to alter dabigatran exposure
(Table 1), as well as the time period between the last
dose of dabigatran etexilate and the trough sample.
Other than the time period, which was treated as a
continuous variable, all of the non-renal covariates
were treated as nominal variables. The dabigatrantrough
values were log-transformed, and were tested for
normality using the D’Agostino–Pearson omnibus test
(with p [ 0.05 indicating that the data passed the
normality test). If these data were judged to be
normally distributed, the log-transformed dabiga-
trantrough values were then converted to z-scores
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(standardised values). Covariates were entered simul-
taneously into a multiple linear regression model based
on biological plausibility rather than statistical criteria.
These covariates included those that have been found
in the literature to significantly correlate with either
dabigatran area under the concentration–time curve
(AUC) or trough plasma concentrations. Using this
model, standardised residuals were generated for each
individual.
2. The estimates of GFR (in units of mL/min) from each
of the four equations were standardised (z-scores) and
then correlated (R2), in turn, with the standardised
residuals from the regression model described above.
The R2 values from each of the four renal function
equations were compared on the basis of the 95 % CI
of each R2 value. Further, the unstandardised residuals,
from the correlation between each renal function
equation and the standardised residuals of the multiple
linear regression model, were compared using repeated
measures one-way analysis of variance (ANOVA).
Finally, the equation with the highest R2 was included
in the multiple linear regression model, and the R2 of
this model for the z-scores of the log-transformed
dabigatrantrough calculated.
These analyses were repeated after excluding patients on
corticosteroids and/or with abnormal thyroid function tests.
Corticosteroid therapy and abnormal thyroid function tests
have been demonstrated to substantially affect plasma cyst-
atin C concentrations [46], and therefore would be expected
to impact on cystatin C-based renal function equations.
As we did not measure the renally cleared active
metabolites of dabigatran, the dabigatran glucuronides, we
correlated the HTI times with the measured dabiga-
trantrough. The HTI assay is a metric for assessing the total
concentration of all thrombin inhibitors, comprising da-
bigatran and its glucuronides, present in the plasma sample
[47]. A high R2 suggests that measured plasma dabigatran
concentrations reflect the concentrations of all thrombin
inhibitors.
As we were not aware of any previous comparison
between the correlations of estimated GFR from renal func-
tion equations with measured dabigatran concentrations, the
data in the literature were considered to be inadequate to
inform an a priori power analysis to calculate sample size.
2.4.2 Comparison of Simulated Dabigatran Etexilate
Dosing Recommendations According to GFR
Equations
Dosing recommendations for dabigatran etexilate in rela-
tion to renal function are available from the manufacturer
[48]. For thromboprophylaxis in the setting of non-valvular
AF, these guidelines recommend dose rates of 150 mg
twice daily and 110 twice daily, for estimated GFR of
[50 mL/min and 30–50 mL/min, respectively, with GFR
\30 mL/min being a contraindication to dabigatran ther-
apy. These guidelines were used to determine recom-
mended dose rates based on the estimated GFR values from
the four equations (Table 2) in the study participants. Each
participant, having four estimates of GFR, would thus have
four recommended dose rates. The percentage of agree-
ment in recommended dose rates was calculated per pair of
GFR equations.
3 Results
The characteristics of the 52 recruited patients are provided
in Table 3. All patients had been on a stable dabigatran
etexilate dose rate for at least 10 days. The mean (SD) of
the dabigatrantrough values was 0.32 (0.26) lg/L per mg/
day. The ABCB1 and CES1 genotype and allele frequencies
of the patients are shown in Table 4.
3.1 Correlation Between GFR Equations
and Dabigatran Concentrations
The log-transformed dabigatrantrough values were found to
be normally distributed (p = 0.98). Of the published non-
renal covariates (Table 1), only the concomitant use of the
P-gp inducers phenytoin and phenobarbitone explained a
significant portion of the variability in dabigatrantrough
values between the 52 patients (p = 0.012, Supplementary
Table 1, electronic supplementary material [ESM]).
Administration of phenytoin and phenobarbitone occurred
in a single individual prescribed dabigatran etexilate
110 mg twice daily who had a low trough plasma dabig-
atran concentration of 9 lg/L (dabigatrantrough = 0.04 lg/
L per mg/day, z-score of the log-transformed dabiga-
trantrough = -3.25). This individual had been electively
admitted for sleep studies, and the blood samples were
taken on the fourth day of his stay as an inpatient. His
hospital prescription chart revealed that dabigatran etexi-
late was administered to him throughout the admission
(total of 6 doses) as per his aforementioned prescribed dose
rate. A multiple linear regression model was constructed
consisting of this covariate, as well as the presence of
concomitant proton-pump inhibitors [11, 12], concomitant
P-gp inhibitors (verapamil and amiodarone) [5, 7] and three
CES1 SNPs (rs8192935, rs2244613 and rs4122238) [13].
The multiple linear regression model that included these
covariates had an unadjusted R2 of 0.29 for the z-scores of
the log-transformed dabigatrantrough.
The R2 values of the four renal function equations for
the standardised residuals of the multiple linear regression
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model are presented in Table 5. All the 95 % CI of the
correlation coefficients overlapped (p = 0.74). Numeri-
cally, the highest R2 value (0.47) was associated with the
CKD-EPI_CrCys equation.
When the estimates of GFR from this equation were
added into the multiple linear regression model, the
unadjusted R2 was 0.69 for the z-scores of the log-trans-
formed dabigatrantrough (Table 6).
No patients were treated with corticosteroids at the time
of the study. Four had abnormal thyroid function test
results, characterised by plasma TSH concentrations (0.28,
4.19, 5.16, 5.61 mU/L) outside the local reference range
(0.40–4.00 mU/L), but with free plasma thyroxine con-
centrations (19, 11, 14, 14 pmol/L, respectively for the
TSH values) that were within the local reference range
(10–24 pmol/L). One of these four patients was the patient
treated with phenytoin and phenobarbitone. Excluding
these patients from the analyses did not significantly
change the results (48 patients, Supplementary Tables 2
and 3 [ESM]).
There was a high correlation (R2 = 0.90) between the
plasma dabigatran concentrations and HTI times, as shown
in Fig. 1.
3.2 Comparison of Simulated Dabigatran Etexilate
Dosing Recommendations According to GFR
Equations
Most of the 52 patients had estimated GFR of[50 mL/min
(92–98 %, depending on the GFR equation). The com-
parisons in dabigatran etexilate dosing recommendations
between pairs of equations are detailed in Table 7, and
show that there was agreement in 94–98 % of comparisons.
4 Discussion
The dosing of renally cleared drugs can be guided by the
use of equations that estimate renal function in the indi-
vidual [23, 49]. The choices of dabigatran etexilate dose
rates, resulting from differences in estimates of GFR
between various renal function equations, have been
compared using simulated data [50, 51]. However, the
correlations of estimated GFR from renal function equa-
tions with measured dabigatran concentrations have not
been compared previously [32]. To our knowledge, the
present study is the first to address this, using trough
plasma dabigatran concentrations at steady-state as the
reference. We demonstrated a clear association between
the estimates of GFR from the renal function equations and
trough plasma dabigatran concentrations at steady-state,
after accounting for non-renal covariates. We did not find
any significant differences between the equations in the
ability to describe inter-individual differences in trough
dabigatran concentrations.
Given that dabigatran is largely cleared by the kidneys
unchanged, it is important to assess and compare the per-
formances of the renal function equations in patients trea-
ted with dabigatran etexilate for the following reasons.
Firstly, as the renal function equations were primarily
developed to gauge GFR, rather than drug clearance, using
these to guide dosing represents a secondary use by
extrapolation [23]. Secondly, given the absence of a vali-
dated method for monitoring the clinical efficacy of da-
bigatran, dose adjustment according to estimated GFR
Table 3 Patient characteristics (n = 52)
Characteristic Median (range)a
Age, years 67 (38–94)
Male, n (%) 41 (79)
Weight, kg 95 (56–187)
Height, m 1.75 (1.55–1.93)
BMI, kg/m2 31.6 (18.4–55.8)
BSA, m2 2.16 (1.61–3.08)
CHA2DS2-VASc 3 (0–7)
HAS-BLED 1 (0–4)
Duration on dabigatran etexilate, weeks 6.0 (1.5–52.0)
Dabigatran etexilate dose rate
75 mg twice daily, n (%) 3 (6)
110 mg twice daily, n (%) 24 (46)
150 mg twice daily, n (%) 25 (48)
GFR equations
CG, mL/min 90 (41–246)
CKD-EPI_Cr, mL/min 87 (38–168)
CKD-EPI_Cys, mL/min 93 (26–149)
CKD-EPI_CrCys, mL/min 88 (40–142)
Proton-pump inhibitor, n (%) 11 (21)
Drugs affecting P-gp functionb
Amiodarone and/or verapamil, n (%) 9 (17)
Phenytoin and phenobarbitone, n (%) 1 (2)
Trough plasma dabigatran concentration, lg/L 60 (9–279)c
Dabigatrantrough, lg/L per mg/day 0.23 (0.04–1.06)
CHA2DS2-VASc and HAS-BLED are scoring systems for assessing
thromboembolic and haemorrhagic risk, respectively, in the setting of
atrial fibrillation [33, 34]. See Table 2 for details of renal function
equations
BMI body mass index, BSA body surface area, CG Cockcroft–Gault
equation, CKD-EPI Chronic Kidney Disease Epidemiology Collab-
oration equation, Cr creatinine, Cys cystatin C, GFR glomerular fil-
tration rate, P-gp P-glycoprotein, dabigatrantrough dose-corrected
trough plasma dabigatran concentration
a Unless stated otherwise
b No patient was on any of the other drugs listed in Table 1
c See Supplementary Fig. 1 (ESM) for a histogram of measured
concentrations
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represents a logical approach to the dose individualisation
of dabigatran etexilate [18, 52]. Finally, while the CG
equation has been recommended for guiding dabigatran
etexilate dosing [5], a previous survey of clinicians
revealed that the majority use the creatinine-only CKD-EPI
equation instead [26].


















C 0.45 0.14 0.48






C 0.44 0.92 0.43






G 0.15 0.41 0.15






T 0.12 0.35 0.12






A 0.26 0.28 0.31
HWE Hardy–Weinberg equilibrium, MAF minor allele frequency, SNP single nucleotide polymorphism
a Utah residents with ancestry from northern and western Europe (CEU) (http://snp.cshl.org/citinghapmap.html.en)
Table 5 Correlation of renal function equations with standardised residuals from the multiple linear regression model for dabigatrantrough
(n = 52)a
Renal function equation R (95 % CI) p Value R2 (95 % CI)
CG -0.56 (-0.74 to -0.31) \0.001 0.32 (0.09–0.55)
CKD-EPI_Cr -0.61 (-0.77 to -0.35) \0.001 0.37 (0.12–0.60)
CKD-EPI_Cys -0.64 (-0.80 to -0.40) \0.001 0.41 (0.16–0.64)
CKD-EPI_CrCys -0.69 (-0.83 to -0.45) \0.001 0.47 (0.20–0.69)
CG Cockcroft–Gault equation, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration equation, Cr creatinine, Cys cystatin C
a Multiple linear regression model for the z-scores of the log-transformed dabigatrantrough, details in Sect. 2.4.1
Table 6 Final multiple linear regression model for z-scores of log-
transformed dabigatrantrough (n = 52)
Predictora B SE (B) p Value
Constant 3.99 1.08 0.001
CKD-EPI_CrCysb -0.69 0.09 \0.001
Time between last dose and sample -0.09 0.06 0.11
Phenytoin and phenobarbitone -2.62 0.65 \0.001
Proton-pump inhibitor -0.55 0.22 0.017
Amiodarone and/or verapamil 0.35 0.23 0.13
rs2244613 0.18 0.47 0.70
rs4122228 -0.13 0.47 0.79
rs8192935 0.03 0.22 0.91
Unadjusted R2 = 0.69
B unstandardised coefficients, SE standard error, CKD-EPI Chronic
Kidney Disease Epidemiology Collaboration, Cr creatinine, Cys
cystatin C
a For all drugs, a value of 1 was assigned to those without the drug,
and a value of 2 assigned to those on the drug. A value of 1 was
assigned to patients who had a wildtype genotype. Patients who were
heterozygous or homozygous for the single nucleotide polymorphism
of interest were assigned a value of 2
b The z-scores of the log-transformed CKD-EPI_CrCys values
Fig. 1 Correlation plot for Hemoclot Thrombin Inhibitor (HTI)
times against trough plasma dabigatran concentrations (n = 52). R2
value is for the line of best fit
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Hijazi et al. [53] recently compared the thromboembolic
and haemorrhagic outcomes observed in a trial comparing
dabigatran with warfarin according to estimated GFR,
using various renal function equations. In patients with a
CKD-EPI C80 mL/min/1.73 m2, dabigatran was associ-
ated with a lower major bleeding rate in comparison with
warfarin (p B 0.005), whereas this was not demonstrable in
patients with CG C80 mL/min (p C 0.061) [53]. Further,
they reported that around 50 % of the dabigatran patients
who were classified as having a creatinine clearance
C80 mL/min according to the CG equation had a GFR
B80 mL/min/1.73 m2 according to the CKD-EPI equation.
Hijazi et al. [53] thus propose that the CKD-EPI equation is
better than the CG equation at identifying patients with
normal or ‘enhanced’ renal function, in whom the risk of
major bleeding is lower for a given dose rate of dabigatran
etexilate. In our study we also observed a greater, albeit
non-significant, correlation with the creatinine-only CKD-
EPI equation compared with the CG equation for trough
dabigatran concentrations (Table 5).
Contemporary renal function equations featuring cysta-
tin C have demonstrated similar or superior performance to
equations employing creatinine [30, 31]. We therefore
sought to examine those cystatin C-based GFR equations
that had been developed using an internationally stand-
ardised cystatin C assay [28]. These include two cystatin
C-based equations developed by the CKD-EPI group [30].
We did not assess the Berlin Initiative Study (BIS) equa-
tion because it was specifically designed for individuals
aged C70 years, of which we had few patients [31]. While
the 95 % CI of the R2 of the four equations overlapped
(Table 5), the CKD-EPI equation featuring both creatinine
and cystatin C was numerically associated with the highest
R2. This is in agreement with the findings of the CKD-EPI
and BIS groups, who found that the equations that
employed both renal biomarkers were superior to those
using either biomarker alone for estimating GFR [30, 31].
Two of the non-renal covariates that appear to have the
largest impact on plasma cystatin C concentrations are
glucocorticoid therapy and thyroid dysfunction [46]. None
of our study population received glucocorticoid therapy.
When patients with thyroid test abnormalities were exclu-
ded, there was no significant change in the results. This
may reflect the mild nature of the test abnormalities, as
evidenced by free thyroxine concentrations within the
‘normal’ reference range.
The agreement in simulated dabigatran etexilate dosing
recommendations between the four GFR equations was
high for our cohort (94–98 %, Table 7). This finding is
predictable given that C92 % of our study participants had
estimated GFR [50 mL/min, with a median GFR of
around 90 mL/min (Table 3). The majority of differences
in estimated GFR between the four equations were thus
away from the 50 mL/min threshold for dose reduction,
and would not be expected to contribute to discordance in
dosing recommendations. We plan to repeat this simulation
in a larger group of patients with moderate to severe
chronic renal impairment who have had creatinine and
cystatin C measured.
The dose-corrected steady-state trough dabigatran con-
centration of the single individual treated with phenytoin
and phenobarbitone (0.04 lg/L per mg/day, in the indi-
vidual with a trough concentration of 9 lg/L on dabigatran
etexilate 110 mg twice daily) was notable as it was more
than 3 SD below the mean dose-corrected trough concen-
tration of our study population (0.32 lg/L per mg/day,
which is equivalent to 70 lg/L on 110 mg twice daily).
Further, it is well below target trough dabigatran concen-
trations that have been suggested in the literature; for
example, Chin et al. [54] have proposed 30–130 lg/L.
While phenytoin and phenobarbitone are known P-gp
inducers, the impact of concomitant use on the pharma-
cokinetics of dabigatran has not previously been reported
[55]. Rifampicin, another P-gp inducer, has been demon-
strated to reduce dabigatran concentrations by around 67 %
[10]. To our knowledge, these are the first data to support
the notion that phenytoin and/or phenobarbitone have a
significant effect on dabigatran concentrations.
Table 7 Comparison of dabigatran dosing recommendations between GFR equations (n = 52)
GFR equation Estimated GFR (mL/min)a Agreement in dosing recommendation between GFR equations
30–50 [50 CKD-EPI_Cr CKD-EPI_Cys CKD-EPI_CrCys
CG 3 (6) 49 (94) 50 (96) 49 (94) 50 (96)
CKD-EPI_Cr 1 (2) 51 (98) 49 (94) 50 (96)
CKD-EPI_Cys 4 (8) 48 (92) 51 (98)
CKD-EPI_CrCys 3 (6) 49 (94)
See Table 2 for details of GFR equations. All results are in n (%). Empty cells represent redundant comparisons
CG Cockcroft–Gault equation, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, Cr creatinine, Cys cystatin C, GFR glomerular
filtration rate
a No patient had an estimated GFR of \30 mL/min for any of the four GFR equations
120 P. K. L. Chin et al.
4.1 Limitations
Our study has several limitations. Firstly, the primary aim,
to assess and compare the correlations of the renal function
equations with trough plasma dabigatran concentrations,
may have been better addressed by gathering data from
individuals given intravenous dabigatran. From such data,
true dabigatran clearance could have been calculated,
without the need to consider oral availability, which is
affected by many covariates (see Table 1). The bias and
imprecision of the renal function equations against dabig-
atran clearance could then have been compared. However,
this approach would also have been more challenging
logistically. By comparison, trough concentrations are a
convenient and useful representation of apparent oral
clearance with which to compare the equations, as these
have been correlated with the risk of thromboembolic and
haemorrhagic outcomes in the setting of AF [4].
Secondly, there could be a statistical power problem
since we had a dataset of only 52 individuals. By com-
paring the equations with the lowest and highest R2 for the
multiple linear regression model for trough plasma dabig-
atran concentrations (CG and CKD-EPI_CrCys, respec-
tively), we calculate that, for future studies, around 680
subjects are needed to have 80 % power (a = 0.05) to
detect a difference between these two equations. This is
valuable data to inform the conduct of future studies.
Thirdly, we did not measure the active precursor of
dabigatran, BIBR 951, or the active metabolites of dabig-
atran, its glucuronides [15]. While BIBR 951 is thought to
have concentrations \0.4 % of those of dabigatran [15],
the dabigatran glucuronides have been reported to make up
10–35 % of the total active drug concentrations following
ingestion of dabigatran etexilate [7, 12, 15, 16, 56, 57].
Given this 3-fold variation in contribution of the glucu-
ronides to the total active drug concentrations, the mea-
surement of dabigatran concentrations alone may not be
representative of total active drug concentrations. The
glucuronides are thought to be cleared renally unchanged,
and are thus relevant when considering the impact of renal
function on total active drug exposure following the
administration of dabigatran etexilate [15]. We chose to
evaluate total active drug concentrations by using the HTI
time. Alternative methods of such evaluation include the
indirect measurement of the dabigatran glucuronides by
alkalinisation of plasma samples to hydrolyse the glucu-
ronides from dabigatran [7, 12, 15, 16, 56, 57], or using a
calibrated HTI assay that determines total dabigatran
concentrations [47]. However, concerns have been
expressed in the literature regarding the validity of the
alkalinisation method, and a detailed description of this
method is yet to be published [54]. Further, the accuracy of
the calibrated HTI assay exceeds FDA bioanalytical quality
limits at total dabigatran concentrations B50 lg/L [47, 58].
As the 10th to 90th percentile of trough total dabigatran
concentrations have been reported to be around 40–220 lg/
L in patients given dabigatran etexilate 150 mg twice daily,
we considered the calibrated HTI assay to be unsuitable for
this study [14]. Instead, we used the HTI time as a gauge of
total dabigatran concentrations for comparison with our
measured dabigatran concentrations. The high R2 of 0.90
between the trough HTI times and our measured trough
plasma dabigatran concentrations is consistent with the
notion that the latter were highly representative of the total
concentration of thrombin inhibitors. Therefore, we expect
that the results of the correlation analyses performed in this
study would be similar if the dabigatran glucuronide con-
centrations were included in the models. To this end, we
repeated the analyses of the four renal function equations,
using the trough HTI times instead of the dabigatrantrough.
A multiple linear regression model for the z-scores of the
log-transformed trough HTI times was constructed. This
included the same covariates as those used in the dabiga-
trantrough model, with the addition of dabigatran etexilate
maintenance dose rates as a scalar covariate. This regres-
sion model had an unadjusted R2 of 0.17 for the z-scores of
the log-transformed trough HTI times. The R2 values of the
four renal function equations for the standardised residuals
of the regression model are presented in Supplementary
Table 4 (ESM). All the 95 % CI of the correlation coeffi-
cients overlapped (p = 0.49), with the highest R2 value
being associated with the CKD-EPI_CrCys equation.
When this equation was added into the multiple linear
regression model, the unadjusted R2 was 0.53 for the z-
scores of the log-transformed trough HTI times (Supple-
mentary Table 5, ESM).
In conclusion, we have demonstrated that the estimates
of renal function using the four renal function equations
explained 32–47 % of the variability in trough plasma
dabigatran concentrations, after other relevant covariates
have been considered. Numerically, the CKD-EPI equation
employing both creatinine and cystatin C had the highest
correlation for trough dabigatran concentrations. In the
setting of a drug for which there is no currently validated
method for monitoring its clinical efficacy, it is useful to
know that all of the tested renal function equations have a
similar capacity to guide adjustment of dabigatran etexilate
dose rates. Further research to determine the impact of each
GFR equation on dabigatran dosing requirements using
simulations from a non-linear mixed model is underway.
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